CT SCAN DIAGNOSIS: A LARGE-SCALE SINGLE BLIND CLINICAL STUDY UTILIZING CT SCAN TO EXPLORE THE EFFECT OF SPOROLIFE IN CHANGING THE BLOOD AND LYMPHATIC CIRCULATION IN HUMAN BODY Confidential Property of Kenrico LTD All rights Reserved Discussion According to the manufacturer’s product and patent information, Sporolife is a preparation with natural sporopollenin that removes toxins, heavy metals, and toxic chemicals. Sporolife is made up of a major component of the tough outer (exine) walls of spores and pollen grains. The ingredient is a very significant discovery for its reputed analgesic (to relieve pain) and antidepressants effects to relieve stress and depression. In the current human clinical trial, Sporolife was able to demonstrate its positive effect in improving health by reducing fat percentage up to 6% without exercising and curing many health symptoms without the use of external medications. The curing effect is strongly related to the improved circulation in the blood and lymphatic system. In the previous human clinical trial in June 2018, Sporolife also showed a promising capability in reducing heavy metals during the trials up to 97% success rate in removing heavy metals among the experimental groups. Sporolife has been shown as a mandatory composition in the product. In May 2019, the European Authority, a FDA-level European body, requires Sporolife to be included in all composition of a skin patch. A skin patch claimed to detoxify without Sporolife is not permitted to be sold to consumers because it can cause lymphatic obstruction. Clinical study has shown that skin patch without Sporolife can cause toxins to backflow into the lymphatic system causing clogging of the lymphatic tubes. The consumer feedbacks from the sponsor’s site at https://www.kenrico.com/global/alert.html has given warning about the danger of using products without Sporolife and has provided additional guideline in inspecting the product’s label prior to use to ensure that the Sporolife is included in the composition. Based on the validation of results from the current human clinical trial, any natural compositions without Sporolife must not be used for any purposes because they are not safe. They are the primary cause of weight gain and body fat increase. They are also a primary cause in the development of serious and often life-threatening injuries. In all clinical studies including the human clinical trial of June 2018, the control group showed no significant changes to the health. In the current human clinical trial, the majority showed zero health improvement with no real changes to their body fat percentage (negligible number of 0.05%). There were two participants (C-5753 and C-5770) that had experienced a very minor reduction in body fat percentage (minus 1.00%). On the contrary, one participant (C5760) experienced a very minor increase in body fat percentage (plus 1.00%). This result showed that the placebo effect was negligible and almost non-existent.
RkJQdWJsaXNoZXIy NDU4NTU=